This is a working overview of Karl Fischer titration, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
=== Cuban linkage and "Namibianisation" === During his final years in office, Vorster had recognised that growing international pressure would eventually force South Africa to grant some form of autonomy or independence to South West Africa. He made token acknowledgements of the UN's role in deciding the territory's future and his administration had publicly renounced the notion of annexation. As Vorster's successor, Botha felt bound by this commitment—at least in principle—to an autonomous South West Africa. His strategy was to cultivate a viable political alternative to SWAPO, preferably moderate and anti-communist in nature, which was committed to close military and security links with South Africa. In the meantime, Botha forestalled further discussions on an internal settlement by demanding the withdrawal of the Cuban armed forces from Angola as a precondition of Namibian independence. Botha argued that the Cuban presence in Angola constituted a legitimate security concern for South West Africa, so it was not unreasonable that independence be contingent on a prior Cuban withdrawal. This initiative was supported by the US, which wanted a Namibian settlement consistent with Western interests, namely a region free of what Chester Crocker termed "Soviet-Cuban military adventurism". Crocker endorsed the linkage since it was related to South West Africa's security situation, which needed to be stabilised prior to independence. Botha's precondition was denounced by SWAPO for arbitrarily tying South West Africa's fate to the resolution of another regional conflict.
monomer A molecule or compound which can exist individually or serve as a building block or subunit of a larger macromolecular aggregate known as a polymer. Polymers form when multiple monomers of the same or similar molecular species are connected to each other by chemical bonds, either in a linear chain or a non-linear conglomeration. Examples include the individual nucleotides which form nucleic acid polymers, the individual amino acids which form polypeptides, and the individual proteins which form protein complexes.
The dawn phenomenon, sometimes called the dawn effect, is an observed increase in blood sugar (glucose) levels that takes place in the early-morning, often between 2 a.m. and 8 a.m. First described by Schmidt in 1981 as an increase of blood glucose or insulin demand occurring at dawn, this naturally occurring phenomenon is frequently seen among the general population and is clinically relevant for patients with diabetes as it can affect their medical management. In contrast to Chronic Somogyi rebound, the dawn phenomenon is not associated with nocturnal hypoglycemia.
Sources: en.wikipedia.org
Hexanauplia (refers to six ("hexa-") naupliar molts)—Copepoda, Thecostraca. Allotriocarida ("allotrios" is "strange", "carida" is "shrimp")—Cephalocarida, Branchiopoda, Remipedia, Hexapoda. Note: the Allotriocarida clade was also recovered in 2005 by Regier et al. as Clade #33, but relations within it were different, and they did not choose a name for it.
yr) by detecting the 39K→38Ar→37Ar decay chain. Above the electroweak scale ΛEW (corresponding to the vacuum expectation value of the Higgs field, around 246 GeV), where Standard Model unification occurs, the three fundamental forces have comparable couplings, suggesting unification in Grand Unified Theories (GUTs). Historical models like Pati–Salam model (1973), unifying quarks/leptons and Georgi–Glashow model (1974), unifying all forces and particles/antiparticles, predict B violation via superheavy gauge bosons MX. The natural GUT energy scale ΛGUT is where SM gauge couplings converge, ~1015 GeV. This value is approximately thirteen orders of magnitude higher than the electroweak scale, or more than eleven orders of magnitude higher than the energy achievable in experiments conducted at particle accelerators. However, at these energies the estimation of proton decay lifetime is around 1029–1031 yr, within reach of dedicated experiments: when GUTs were proposed, the experimental limits were around 1030 yr (for decay modes which produce 𝜇 →𝑒 decays). These considerations strongly motivated proton decay searches. In 1981 was published the first limit by a water Cherenkov detector at the Homestake gold mine, looking for the production and detection of a decaying muon following a nucleon decay event:
==== Aqueous solutions ==== Aqueous solutions are solutions of a compound with water. In contrast to other formulations, such as oil solutions, aqueous suspensions, and emulsions, aqueous solutions of estradiol and estradiol esters by intramuscular injection are not depot injections. Instead, they are rapidly absorbed and eliminated, analogously to intravenous injections of estradiol and estradiol esters. The durations of aqueous solutions of estradiol and estradiol esters by intramuscular injection are measured in hours.
=== Gene expression === PLP has been implicated in increasing or decreasing the expression of certain genes. Increased intracellular levels of the vitamin lead to a decrease in the transcription of glucocorticoids. Vitamin B6 deficiency leads to the increased gene expression of albumin mRNA. Also, PLP influences expression of glycoprotein IIb by interacting with various transcription factors; the result is inhibition of platelet aggregation.
Sources: en.wikipedia.org
Microorganisms have a much higher growth rate (algae: 2–6 hours, yeast: 1–3 hours, bacteria: 0.5–2 hours). This also allows selection for strains with high yield and good nutritional composition more quickly and easily compared to breeding. Whereas large parts of crops, such as stems, leaves and roots, are not edible, single-cell microorganisms can be used entirely. Whereas parts of the edible fraction of crops are indigestible, many microorganisms are digestible at a much higher fraction. Microorganisms usually have a much higher protein content of 30–70% in the dry mass than vegetables or grains. The amino acid profiles of many SCP microorganisms often have excellent nutritional quality, comparable to hen's eggs. Some microorganisms can build vitamins and nutrients which eukaryotic organisms such as plants cannot produce or not produce in significant amounts, including vitamin B12. Microorganisms can utilize a broad spectrum of raw materials as carbon sources including alkanes, methanol, methane, ethanol and sugars. What was considered "waste product" often can be reclaimed as nutrients and support growth of edible microorganisms. Like plants, autotrophic microorganisms are capable of growing on CO2. Some of them, such as bacteria with the Wood–Ljungdahl pathway or the reductive TCA can fix CO2 with efficiencies ranging from 2-3 times to 10 times more efficiently than plants, when also considering the effects of photoinhibition. Some bacteria, such as several homoacetogenic clostridia, are capable of performing syngas fermentation.
These investigations included key studies by Francis Dumont and Nolan Sigal at Merck contributing to show that FK506 and rapamycin behave as reciprocal antagonists. These studies implicated FKBP12 as a possible target of rapamycin, but suggested that the complex might interact with another element of the mechanistic cascade. In 1991, calcineurin was identified as the target of FKBP12-FK506. That of FKBP12-rapamycin remained mysterious until genetic and molecular studies in yeast established FKBP12 as the target of rapamycin, and implicated TOR1 and TOR2 as the targets of FKBP12-rapamycin in 1991 and 1993, followed by studies in 1994 when several groups, working independently, discovered the mTOR kinase as its direct target in mammalian tissues. Sequence analysis of mTOR revealed it to be the direct ortholog of proteins encoded by the yeast target of rapamycin 1 and 2 (TOR1 and TOR2) genes, which Joseph Heitman, Rao Movva, and Michael N. Hall had identified in August 1991 and May 1993. Independently, George Livi and colleagues later reported the same genes, which they called dominant rapamycin resistance 1 and 2 (DRR1 and DRR2), in studies published in October 1993. The protein, now called mTOR, was originally named FRAP by Stuart L. Schreiber and RAFT1 by David M. Sabatini; FRAP1 was used as its official gene symbol in humans. Because of these different names, mTOR, which had been first used by Robert T.
=== Reform and further enlargement === East Germany joined on 3 October 1990 through reunification with West Germany. In the 1990s, several European countries, now members of the European Union, expressed their willingness to join the Organisation. In 1995, Cyprus applied for membership, but according to the Cypriot government, it was vetoed by Turkey. In 1996, Estonia, Latvia, and Lithuania signed a Joint Declaration expressing willingness to become members of the OECD, and Slovenia also applied for membership that same year. In 2005, Malta applied to join the Organisation. The EU is lobbying for the admission of all EU member states. Romania reaffirmed in 2012 its intention to become a member of the Organisation through the letter addressed by Romanian Prime Minister Victor Ponta to OECD Secretary-General José Ángel Gurría. In September 2012, the government of Bulgaria confirmed it would apply for membership before the OECD Secretariat. The OECD established a working group headed by ambassador Seiichiro Noboru to work out a plan for the enlargement with non-members.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.